Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38   
Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.

En als donateur kunt u ook korting krijgen bij verschillende bedrijven: 

https://kanker-actueel.nl/NL/voordelen-van-ops-lidmaatschap-op-een-rijtje-gezet-inclusief-hoe-het-kookboek-en-de-recepten-op-basis-van-uitgangspunten-van-houtsmullerdieet-te-downloaden-enof-in-te-zien.html

Bron: Nutr Cancer. 2015;67(3):457-62. doi: 10.1080/01635581.2015.1004734. Epub 2015 Mar 24.

Hoe simpel kan het soms zijn. Operaties in het gebied rondom de alvleesklier zijn vaak heel riskant en kunnen voor zeer ernstige complicaties zorgen. Vaak overlijden mensen tijdens of ten gevolge van de operatie met name door infecties. Uit een placebo gecontroleerde gerandomiseerde studie met patienten die werden geopereerd aan een zogeheten Periampullary neoplasms (kwaadaardige tumoren rondom de overgang van alvleesklier en maag) blijkt dat wanneer patienten in de weken voor de operatie voor totaal 14 dagen 2x per dag een mix namen van probiotica en synbiotica dan bleken deze patienten veel beter beschermd tegen ernstige complicaties.

synbiotica 2

Wat heet beter beschermd. Uit de groep van 23 patiënten die een placebo kregen overleden 6 patiënten (= 25%) tijdens of kort daarop aan de gevolgen van de operatie, ten gevolge van infecties. Van de 23 patienten die synbiotica hadden gekregen overleed niemand.

De synbiotica bestond uit Lactobacillus acidophilus 10, 1 × 10(9)CFU, Lactobacillus rhamnosus HS 111, 1 × 10(9) CFU, Lactobacillus casei 10, 1 × 10(9) CFU, Bifidobacterium bifidum, 1 × 10(9)CFU, en fructooligosaccharides (FOS) 100 mg.

Ook het optreden van postoperatieve infecties was statistisch significant lager in de groep van de synbiotica (6 van 23 patiënten hadden een infectie, 26.1%) dan in de placebogroep (16 van de 23 patiënten kregen een infectie, 69.6%) (P = 0.00). Duur van de antibiotica was ook veel kroter in de synbioticagroep (gemiddeld 9 dagen versus. 15 dagen in de placebogroep; P = 0.01). Niet infectueuze complicaties waren ook veel minder in de synbioticagroep (6 uit 23 versus. 14 uit 23 patiënten in de placebogroep; P = 0.03). De lengte van verblijf in het ziekenhuis bleek 5 tot 12 dagen te zijn in de synbioticagroep versus  14 tot 23 dagen in de placebogroep (P = 0.00). En zoals eerder gezegd in de placebogroep waren 6 sterfgevallen ten gevolge van de operatie tegenover geen doden in de synbioticagroep. (P = 0.02)

Dat probiotica en synbiotica vooraf aan operaties in met name de spijsverteringsorganen ernstige complicaties kan tegengaan is al veel langer bekend. Zie o.a. dit studierapport: Perioperative Synbiotic Treatment to Prevent Postoperative Infectious Complications in Biliary Cancer Surgery gratis in te zien:  met een referentielijst die veel meer studies vermeld rondom dit onderwerp. Referentielijst van deze studie staat onderaan dit artikel Maar ik vermoed dat dit in veel ziekenhuizen niet zal worden toegepast. Waarom toch niet. Het is toch eigenlijk heel simpel en spotgoedkoop en voorkomt zeer ernstig leed voor de patienten.

Het volledige studierapport: Perioperative synbiotics decrease postoperative complications in periampullary neoplasms: a randomized, double-blind clinical trial is tegen betaling in te zien.

Hier het abstract van deze studie:

Perioperative administration of synbiotics reduces postoperative mortality and complication rates in patients undergoing surgery for Periampullary neoplasms

Nutr Cancer. 2015;67(3):457-62. doi: 10.1080/01635581.2015.1004734. Epub 2015 Mar 24.

Perioperative synbiotics decrease postoperative complications in periampullary neoplasms: a randomized, double-blind clinical trial.

Author information

  • 1a Post Graduate Program in Medicine - Surgical Sciences , Universidade Federal do Rio Grande do Sul School of Medicine , Porto Alegre , Brazil.

Abstract

Periampullary neoplasms are rapidly progressive tumors with a poor prognosis and high morbidity and mortality rates, which have a negative influence on patient outcomes. Some probiotics and prebiotics have the ability to protect the intestinal barrier and prevent bacterial translocation, infection, and postoperative complications. We evaluated the use of synbiotics in a prospective, double-blind study of patients undergoing surgery for periampullary neoplasms (PNs) and assessed the effect of these agents on nutritional status, postoperative complications, antibiotic use, length of hospital stay, and mortality. Patients were randomized to receive probiotics and prebiotics-synbiotics--group S [Lactobacillus acidophilus 10, 1 × 10(9)CFU, Lactobacillus rhamnosus HS 111, 1 × 10(9) CFU, Lactobacillus casei 10, 1 × 10(9) CFU, Bifidobacterium bifidum, 1 × 10(9)CFU, and fructooligosaccharides (FOS) 100 mg]--or placebo-controls--group C, twice daily, for a total of 14 days. Risk, clinical status, and postoperative complication rates were assessed. Twenty-three patients were allocated to each group. The incidence of postoperative infection was significantly lower in group S (6 of 23 patients, 26.1%) than in group C (16 of 23 patients, 69.6%) (P = 0.00). Duration of antibiotic therapy was also shorter in group S (mean = 9 days vs. 15 days in group C; P = 0.01). Noninfectious complications were less common in group S (6 of 23 vs. 14 of 23 patients in group C; P = 0.03). Mean length of hospital stay was 12 ± 5 days in group S vs. 23 ± 14 days in group C (P = 0.00). No deaths occurred in group S, whereas 6 deaths occurred in group C (P = 0.02). Perioperative administration of synbiotics reduces postoperative mortality and complication rates in patients undergoing surgery for PNs.

PMID:
25803626
[PubMed - indexed for MEDLINE]

Referenties van studies met synbiotica en probiotica in de galwegen en spijsverteringsorganen

1. Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73(suppl):444–450. [PubMed]
2. Anderson AS. Lifestyle interventions: how joined up are we? J Hum Nutr Diet. 2002;15:241–242. [PubMed]
3. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol. 1999;6:186–192. [PMC free article] [PubMed]
4. Ishikawa H, Saito H, Suzuki K. New gut associated lymphoid tissue: cryptopatches breed murine intestinal intraepitherial T cell precursors. Immunol. Res. 1999;20:243–250. [PubMed]
5. Parks RW, Clements WD, Pope C, et al. Bacterial translocation and gut microflora in obstructive jaundice. J Anat. 1996;189(Pt 3):561–565. [PMC free article] [PubMed]
6. Welsh FK, Ramsden CW, MacLennan K, et al. Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg. 1998;227:205–212. [PMC free article] [PubMed]
7. Gouma DJ, Coelho JC, Fisher JD, et al. Endotoxemia after relief of biliary obstruction by internal and external drainage in rats. Am J Surg. 1986;151:476–479. [PubMed]
8. Nimura Y, Hayakawa N, Kamiya J, et al. Combined portal vein and liver resection for carcinoma of the biliary tract. Br J Surg. 1991;78:727–731. [PubMed]
9. Nagino M, Nimura Y, Hayakawa N, et al. Logistic regression and discriminant analyses of hepatic failure after liver resection for carcinoma of the biliary tract. World J Surg. 1993;17:250–255. [PubMed]
10. Nimura Y, Kamiya J, Nagino M, et al. Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 1998;5:52–61. [PubMed]
11. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808–818; discussion 819. [PMC free article] [PubMed]
12. Nagino M, Kamiya J, Uesaka K, et al. Complications of hepatectomy for hilar cholangiocarcinoma. World J Surg. 2001;25:1277–1283. [PubMed]
13. Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992;215:503–511; discussion 511–513. [PMC free article] [PubMed]
14. Shirabe K, Matsumata T, Shimada M, et al. A comparison of parenteral hyperalimentation and early enteral feeding regarding systemic immunity after major hepatic resection: the results of a randomized prospective study. Hepatogastroenterology. 1997;44:205–209. [PubMed]
15. Zulfikaroglu B, Zulfikaroglu E, Ozmen MM, et al. The effect of immunonutrition on bacterial translocation, and intestinal villus atrophy in experimental obstructive jaundice. Clin Nutr. 2003;22:277–281. [PubMed]
16. Anderson AD, McNaught CE, Jain PK, et al. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut. 2004;53:241–245. [PMC free article] [PubMed]
17. Shu Q, Gill HS. Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol. 2002;34:59–64. [PubMed]
18. Eizaguirre I, Urkia NG, Asensio AB, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg. 2002;37:699–702. [PubMed]
19. Gill HS, Shu Q, Lin H, et al. Protection against translocating Salmonella typhimurium infection in mice by feeding the immuno-enhancing probiotic Lactobacillus rhamnosus strain HN001. Med Microbiol Immunol (Berl). 2001;190:97–104. [PubMed]
20. Fuller R. Probiotics in human medicine. Gut. 1991;32:439–442. [PMC free article] [PubMed]
21. Gibson GR, Beatty ER, Wang X, et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108:975–982. [PubMed]
22. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr. 1999;69(suppl):1052–1057. [PubMed]
23. McNaught CE, Woodcock NP, MacFie J, et al. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut. 2002;51:827–831. [PMC free article] [PubMed]
24. Rayes N, Hansen S, Seehofer D, et al. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition. 2002;18:609–615. [PubMed]
25. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74:123–127. [PubMed]
26. Kanazawa H, Nagino M, Kamiya S, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg. 2005;390:104–113. [PubMed]
27. Kamiya S, Nagino M, Kanazawa H, et al. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg. 2004;239:510–517. [PMC free article] [PubMed]
28. Jansen G, Muskiet FA, Schierbeek H, et al. Capillary gas chromatographic profiling of urinary, plasma and erythrocyte sugars and polyols as their trimethylsilyl derivatives, preceded by a simple and rapid prepurification method. Clin Chim Acta. 1986;157:277–293. [PubMed]
29. Takagi K, Nakao M, Ogura Y, et al. Sensitive colorimetric assay of serum diamine oxidase. Clin Chim Acta. 1994;226:67–75. [PubMed]
30. Nagao F, Yabe T, Xu M, et al. Application of non-radioactive europium (Eu3+) release assay to a measurement of human natural killer activity of healthy and patient populations. Immunol Invest. 1996;25:507–518. [PubMed]
31. Gaines Das RE, Poole S. The international standard for interleukin-6. Evaluation in an international collaborative study. J Immunol Methods. 1993;160:147–153. [PubMed]
32. Azuma R, Suto T. Validity of transfer of the taxonomical position of Corynebacterium pseudopyogenes from genus Corynebacterium to genus Actinomyces. In: Izuka H, Hasegawa T, eds. Proceeding of the First International Conference on Culture Collection. Tokyo: University of Tokyo, 1970:493–505.
33. Tanaka R, Mutai M. Improved medium for selective isolation and enumeration of Bifidobacterium. Appl Environ Microbiol. 1980;40:866–869. [PMC free article] [PubMed]
34. Petts DN. Colistin-oxolinic acid-blood agar: a new selective medium for streptococci. J Clin Microbiol. 1984;19:4–7. [PMC free article] [PubMed]
35. Sonoike K, Mada M, Mutai M. Selective agar medium for counting viable cells of bifidobacteria in fermented milk. J Food Hyg Soc Jpn. 1986;27:238–244.
36. Kitajima H, Sumia Y, Tanaka R, et al. Early administration of Biffidobacterium Breve to preterm infants: randomized controlled trial. Arch Dis Child. 1997;76:101–107. [PMC free article] [PubMed]
37. Kikuchi H, Yajima T. Correlation between water-holding capacity of different types of cellulose in vitro and gastrointestinal retention time in vivo of rats. J Sci Food Agr. 1992;60:139–146.
38. Shigeta H, Nagino M, Kamiya J, et al. Bacteremia after hepatectomy: an analysis of a single-center, 10-year experience with 407 patients. Langenbecks Arch Surg. 2002;387:117–124. [PubMed]
39. Kanai M, Nimura Y, Kamiya J, et al. Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery. 1996;119:498–504. [PubMed]
40. Deitch EA. Nutrition and the gut mucosal barrier. Curr Opin Gen Surg. 1993;85–91. [PubMed]
41. Nagao F, Nakayama M, Muto T, et al. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol Biochem. 2000;64:2706–2708. [PubMed]
42. Sheih YH, Chiang BL, Wang LH, et al. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001;20:149–156. [PubMed]
43. Matsuzaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol. 2000;78:67–73. [PubMed]
44. Iwata H, Matsushita M, Nishikimi N, et al. Intestinal permeability is increased in patients with intermittent claudication. J Vasc Surg. 2000;31:1003–1007. [PubMed]
45. McNaught CE, Woodcock NP, Anderson AD, et al. A prospective randomised trial of probiotics in critically ill patients. Clin Nutr. 2005;24:211–219. [PubMed]
46. Shida K, Makino K, Morishita A, et al. Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int Arch Allergy Immunol. 1998;115:278–287. [PubMed]
47. Kato I, Tanaka K, Yokokura T. Lactic acid bacterium potently induces the production of interleukin-12 and interferon-gamma by mouse splenocytes. Int J Immunopharmacol. 1999;21:121–131. [PubMed]
48. Takagi A, Matsuzaki T, Sato M, et al. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis. 2001;22:599–605. [PubMed]
49. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996;77:110–117. [PubMed]
50. Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth. 1997;78:201–219. [PubMed]
51. Duc le H, Hong HA, Barbosa TM, et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol. 2004;70:2161–2171. [PMC free article] [PubMed]
52. Bartosch S, Woodmansey EJ, Paterson JC, et al. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis. 2005;40:28–37. [PubMed]
53. Mitsuoka T. Significance of dietary modulation of intestinal flora and intestinal enviroment. Biosci Microflora. 2000;19:15–25.
54. Sakata T. Effect of short-chain fatty acids on the proliferation of gut epithelial cells in vivo. In: Cummings J, Rombeau J, Sakata T, eds. Physiological and Clinical Aspects of Short-Chain Fatty Acids. Cambridge: Cambridge University Press, 1995:191–208.
55. Cherbut C. Effects of short-chain fatty acids on gastrointestinal motility. In: Cummings J, Rombeau J, Sakata T, eds. Physiological and Clinical Aspects of Short-Chain Fatty Acids. Cambridge: Cambridge University Press, 1995:191–208.
56. Willemsen LE, Koetsier MA, van Deventer SJ, et al. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut. 2003;52:1442–1447. [PMC free article] [PubMed]

Plaats een reactie ...

Reageer op "Synbiotica pre operatief voorkomt hoog significant ernstige complicaties bij operaties in gebied van alvleesklier. 6 versus geen sterfgevallen tijdens operatie"


Gerelateerde artikelen
 

Gerelateerde artikelen

Immunonutrition - immuunstimulerend >> Synbiotica pre operatief voorkomt >> Vitamine D - calcipotriol >> L-carnitine, een aminozuur, >> Triptolide, een werkzame stof >> Ukrain al of niet in combinatie >> Ukrain een natuurlijk product >> Voeding en voedingsstoffen: >>